SB 568849

Drug Profile

SB 568849

Latest Information Update: 30 Nov 2004

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Anxiolytics; Obesity therapies
  • Mechanism of Action Melanin-concentrating hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Obesity

Most Recent Events

  • 30 Nov 2004 Discontinued - Preclinical for Obesity in United Kingdom (unspecified route)
  • 30 Nov 2004 Discontinued - Preclinical for Anxiety disorders in United Kingdom (unspecified route)
  • 23 Sep 2002 Preclinical trials in Obesity in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top